Get the Stockscreener App
30.61
4.73%
-1.52
After Hours:
30.76
0.15
+0.49%
Cytokinetics Inc stock is traded at $30.61, with a volume of 3.47M.
It is down -4.73% in the last 24 hours and down -20.80% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$32.13
Open:
$32.35
24h Volume:
3.47M
Relative Volume:
1.62
Market Cap:
$4.06B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-5.8194
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-9.89%
1M Performance:
-20.80%
6M Performance:
-45.30%
1Y Performance:
-47.12%
1-Day Range:
$30.46
$32.95
1-Week Range:
$30.46
$35.36
52-Week Range:
$30.46
$61.40
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
30.61 | 4.06B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Aficamten outperforms beta blocker in HCM trial - Investing.com
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - Eagle-Tribune
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
5,400 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Raymond James Financial Inc. - Defense World
Cytokinetics, Incorporated Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- CYTK - ACCESS Newswire
FY2025 EPS Estimates for Cytokinetics Lowered by Analyst - Defense World
Barclays Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $53.00 - Defense World
HC Wainwright Has Weak Estimate for Cytokinetics Q2 Earnings - Defense World
What is B. Riley’s Estimate for Cytokinetics Q2 Earnings? - Defense World
Leerink Partnrs Predicts Lower Earnings for Cytokinetics - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Royal Bank of Canada Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress - Stock Titan
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Cytokinetics (CYTK) Maintains Overweight Rating Despite Price Target Cut | CYTK Stock News - GuruFocus
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating - marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytokinetics shares hold as JMP reiterates $78 price target By Investing.com - Investing.com Nigeria
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights By Investing.com - Investing.com Nigeria
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
CYTK: Citigroup Lowers Price Target for Cytokinetics | CYTK Stoc - GuruFocus
Cytokinetics Inc earnings beat by $0.01, revenue fell short of estimates - Investing.com Nigeria
Cytokinetics to Hold Annual Meeting of Stockholders - Yahoo Finance
Cytokinetics (CYTK) Price Target Adjusted by RBC Capital | CYTK Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended - Yahoo Finance
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook - Seeking Alpha
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com Australia
Cytokinetics (CYTK) Price Target Adjusted as FDA Decision Delayed | CYTK Stock News - GuruFocus
Cytokinetics shares hold as JMP reiterates $78 price target - Investing.com
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges By GuruFocus - Investing.com Canada
Cytokinetics (CYTK) Advances Aficamten Commercialization Plans - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics: Q1 Earnings Snapshot - The Washington Post
Cytokinetics (CYTK) Misses Q1 Revenue Estimates and Advances Car - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings: EPS of -$1.36 Beats Es - GuruFocus
Earnings call transcript: Cytokinetics reports Q1 2025 net loss, stock dips - Investing.com India
Cytokinetics Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Cytokinetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
May 06 '25 |
Sale |
35.01 |
2,000 |
70,020 |
140,255 |
| Callos Andrew | EVP, Chief Commercial Officer |
May 05 '25 |
Sale |
36.68 |
4,002 |
146,793 |
60,687 |
| Blum Robert I | President & CEO |
Apr 29 '25 |
Sale |
40.96 |
5,000 |
204,800 |
417,629 |
| Malik Fady Ibraham | EVP Research & Development |
Apr 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,255 |
| Malik Fady Ibraham | EVP Research & Development |
Apr 22 '25 |
Sale |
38.11 |
2,000 |
76,220 |
140,255 |
| WIERENGA WENDALL | Director |
Apr 21 '25 |
Option Exercise |
6.21 |
20,000 |
124,200 |
44,848 |
| WIERENGA WENDALL | Director |
Apr 21 '25 |
Sale |
38.46 |
20,000 |
769,200 |
24,848 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):